Eminase

Eminase Uses, Dosage, Side Effects, Food Interaction and all others data.

Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins.

Eminase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.

Trade Name Eminase
Availability Discontinued
Generic Anistreplase
Anistreplase Other Names Anisoylated plasminogen streptokinase activator complex, Anistreplase, APSAC
Related Drugs aspirin, lisinopril, metoprolol, propranolol, Plavix, Brilinta
Type
Formula C2569H3928N746O781S40
Weight 59042.3 Da
Groups Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Eminase
Eminase

Uses

Eminase is a form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.

For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction

How Eminase works

Eminase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots.

Food Interaction

  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Eminase Hypertension interaction

[Major] The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma

Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy.

Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy.

Measures of fibrinolytic activity and

Eminase Disease Interaction

Major: bleeding risks

Innovators Monograph

You find simplified version here Eminase

*** Taking medicines without doctor's advice can cause long-term problems.
Share